Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ACET
Adicet Bio, Inc. Common Stock
stock NASDAQ

At Close
Jun 25, 2025 3:59:30 PM EDT
0.6600USD+0.887%(+0.0058)359,438
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Jun 26, 2025 8:24:30 AM EDT
0.6800USD+3.343%(+0.0220)982
After-hours
Jun 25, 2025 4:50:30 PM EDT
0.6581USD-0.288%(-0.0019)443
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 10, 2021
04:01PM EST  Adicet Bio, Inc. Announces Closing of $100 Million Public   GlobeNewswire Inc
Dec 8, 2021
08:19AM EST  The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom   Benzinga
05:48AM EST  Adicet Bio Priced 6.25M Share Public Offering of Common Stock @$14/Share   Benzinga
01:13AM EST  Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
Dec 7, 2021
04:17PM EST  Adicet Bio Reports Offering Of Common Shares, No Size Disclosed   Benzinga
04:16PM EST  Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock   GlobeNewswire Inc
Dec 6, 2021
02:31PM EST  Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher   Benzinga
12:30PM EST  Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge   Benzinga
11:20AM EST  Guggenheim Maintains Buy on Adicet Bio, Raises Price Target to $32   Benzinga
10:12AM EST  UPDATE: Guggenheim Reiterates Buy Rating On Adicet Bio   Benzinga
10:03AM EST  Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings   Benzinga
07:18AM EST  Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy   Benzinga
07:00AM EST  Adicet Bio Announces PositiveInterim Clinical   GlobeNewswire Inc
Nov 29, 2021
07:00AM EST  ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data   GlobeNewswire Inc
Nov 18, 2021
07:00AM EST  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.   GlobeNewswire Inc
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:10AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:09AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:00AM EST  Adicets allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Companys gamma delta T cell platform   GlobeNewswire Inc
Nov 10, 2021
04:53PM EST  Adicet Bio Q3 EPS $(0.44) Up From $(2.84) YoY   Benzinga
04:01PM EST  -- On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year end -- Announced collaboration with Twist Bioscience to accelerate discovery of gamma delta T cell cancer therapeutics and expand pipeline   GlobeNewswire Inc
Nov 8, 2021
07:00AM EST  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference taking place on November 15-17, 2021.   GlobeNewswire Inc
Oct 12, 2021
04:10PM EDT  Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief   GlobeNewswire Inc
Oct 4, 2021
07:14AM EDT  Adicet To Present Preclinical Data From Allogeneic Gamma Delta T Cell Platform At SITC 36th Annual Meeting   Benzinga
07:00AM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36thAnnual Meeting to be held November 10-14, 2021.   GlobeNewswire Inc
Sep 13, 2021
08:00AM EDT  Adicet Bio Collaborates with Twist Bioscience to Accelerate   GlobeNewswire Inc
Sep 2, 2021
04:54PM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in September.   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:04AM EDT  08:03 Tuesday, August 17, 2021Wedbush (RTTNews) - Wedbush Reiterates Adicet Bio, Inc (ACET) At Outperform With $25 Price Target   RTTNews
Aug 12, 2021
04:26PM EDT  Adicet Bio Q2 EPS $(0.34) Up From $(3.88) YoY   Benzinga
04:01PM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the second quarter ended June 30, 2021.   GlobeNewswire Inc
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Aug 2, 2021
07:00AM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in three upcoming virtual investor conferences in August.   GlobeNewswire Inc
Jul 30, 2021
04:15PM EDT  Adicet Bio In 8K Filing Says Delivered Written Notice To Novartis To Terminate Certain License Agreement, Effective On Or Before Oct. 1, 2021; Says Co. Is Not Subject To Any Termination Penalties Related To Termination Of License Agreement   Benzinga
04:13PM EDT  Adicet Bio Says Delivered Written Notice To Novartis To Terminate Certain License Agreement, Effective On Or Before Oct. 1, 2021; Says Co. Is Not Subject To Any Termination Penalties Related To Termination Of License Agreement   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
07:00AM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the formation of a Scientific Advisory Board (SAB). The SAB is comprised of renowned scientific leaders in the fields of T cell biology, immunology, and oncology.   GlobeNewswire Inc
Jul 14, 2021
07:48AM EDT  The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jun 28, 2021
07:00AM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company has been added to the Russell 2000 Index, effective June 28, 2021, as part of the 2021 Russell indexes annual reconstitution.   GlobeNewswire Inc
Jun 24, 2021
08:12AM EDT  The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 3, 2021
10:27AM EDT  Adicet ClinicalTrials.gov Study Record Detail For Co.'s 'Long-Term Follow-up Study for Subjects Treated With Adicet Bio T Cell Investigational Products,' Shows Not Yet Recruiting   Benzinga
May 18, 2021
04:10PM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in May and June.   GlobeNewswire Inc
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021   Benzinga
07:44AM EDT  BTIG Initiates Coverage On Adicet Bio with Buy Rating, Announces Price Target of $34   Benzinga
May 17, 2021
07:15AM EDT  Adicet Bio Q1 EPS $(0.82) Up From $(2.07) YoY   Benzinga
07:01AM EDT  -- Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021   GlobeNewswire Inc
Apr 29, 2021
10:32AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2021   Benzinga
08:56AM EDT  JonesTrading Initiates Coverage On Adicet Bio with Buy Rating, Announces Price Target of $33   Benzinga
07:00AM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will present at the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021 at 2:40 PM ET.   GlobeNewswire Inc
Apr 23, 2021
12:03PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 23, 2021   Benzinga
07:13AM EDT  HC Wainwright & Co. Initiates Coverage On Adicet Bio with Buy Rating, Announces Price Target of $27   Benzinga
Apr 15, 2021
07:00AM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.   GlobeNewswire Inc
Apr 14, 2021
01:20PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021   Benzinga
07:11AM EDT  Canaccord Genuity Initiates Coverage On Adicet Bio with Buy Rating, Announces Price Target of $28   Benzinga
Apr 13, 2021
07:00AM EDT  Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research   GlobeNewswire Inc
Apr 8, 2021
10:52AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021   Benzinga
07:06AM EDT  Guggenheim Initiates Coverage On Adicet Bio with Buy Rating, Announces Price Target of $22   Benzinga
Mar 12, 2021
06:47AM EST  Adicet Bio S-3 Shows Registration For $300M Mixed Securities Shelf Offering   Benzinga
Mar 11, 2021
04:33PM EST  Adicet Bio Q4 EPS $(0.46) Up From $(3.05) YoY   Benzinga
04:10PM EST  -- Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an anti-CD20 allogeneic CAR gamma-delta T cell therapy, interim clinical data expected in 2021 -- Successfully raised $143.6 million in net proceeds through a public offering and concurrent private placement to advance a pipeline of CAR gamma-delta T cell therapies   GlobeNewswire Inc
Mar 10, 2021
07:10AM EST  Adicet Bio Initiates First-In-Human Phase 1 Trial Of ADI-001 For Treatment Of B Cell Non-Hodgkin's Lymphoma   Benzinga
07:02AM EST  Adicet Bio Begins First-in-Human Phase 1 Trial Of ADI-001 For B Cell Non-Hodgkin's Lymphoma   RTTNews
07:01AM EST  Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001   PR Newswire
Mar 4, 2021
04:01PM EST  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors.   GlobeNewswire Inc
Feb 16, 2021
07:00AM EST  Adicet Bio, Inc. Announces Closing of $152 Million Public Offering   GlobeNewswire Inc
Feb 11, 2021
07:00AM EST  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the company management will participate in three upcoming virtual investor conferences.   GlobeNewswire Inc
Feb 10, 2021
07:53AM EST  Adicet Bio Prices 9,230,770 Share Common Stock Offering At $13/Share; In Connection With Offering, Co. Enters Stock Purchase Agreement With Existing Investors For $15M   Benzinga
07:51AM EST  Adicet Bio, Inc. Announces Pricing of $135   GlobeNewswire Inc
Feb 9, 2021
04:05PM EST  Adicet Bio Announces A Common Stock Offering And Concurrent Private Placement; No Terms Disclosed   Benzinga
04:04PM EST  Adicet Bio, Inc. Announces Proposed Public Offering of Common   GlobeNewswire Inc
Jan 7, 2021
07:00AM EST  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January.   GlobeNewswire Inc
Dec 8, 2020
07:00AM EST  Adicet Bio to Participate in Fireside Chat at JMP Securities   GlobeNewswire Inc
Dec 1, 2020
07:00AM EST  Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of   GlobeNewswire Inc
Nov 6, 2020
07:00AM EST  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in upcoming virtual investor conferences and events in November and December.   GlobeNewswire Inc
Nov 5, 2020
05:44PM EST  Adicet Bio Q3 EPS $(2.84) Up From $(6.87) YoY, Sales $3.028M   Benzinga
Nov 4, 2020
10:26AM EST  Benzinga's Top Upgrades, Downgrades For November 4, 2020   Benzinga
06:51AM EST  B. Riley FBR Initiates Coverage On Adicet Bio with Buy Rating, Announces Price Target of $30   Benzinga
Oct 26, 2020
04:26PM EDT  Adicet Appoints Don Healey, Ph.D., As Chief Technology Officer   Benzinga
Oct 22, 2020
07:22AM EDT  Adicet Announces FDA Clearance Of IND Application For Allogeneic CAR Gamma-Delta T Cell Therapy   RTTNews
07:05AM EDT  Adicet Announces FDA Clearance Of IND Application For First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy   Benzinga
07:00AM EDT  Adicet Announces FDA Clearance of IND Application for   GlobeNewswire Inc
Oct 16, 2020
09:40AM EDT  Benzinga's Top Upgrades, Downgrades For October 16, 2020   Benzinga
05:42AM EDT  Wedbush Initiates Coverage On Adicet Bio with Outperform Rating, Announces Price Target of $25   Benzinga
Oct 1, 2020
04:10PM EDT  Adicet Bio to Present at the Jefferies Cell Therapy Summit   GlobeNewswire Inc
Sep 23, 2020
02:57PM EDT  Mid-Afternoon Market Update: Dow Tumbles 400 Points; JinkoSolar Shares Jump   Benzinga
12:20PM EDT  Mid-Day Market Update: Gold Falls 2%; SPI Energy Shares Spike Higher   Benzinga
11:29AM EDT  Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates   Benzinga
10:58AM EDT  Why Adicet Bio's Stock Is Trading Higher Today   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates   Benzinga
05:25AM EDT  Adicet Bio Announced Not Proceeding with Previously Announced Public Offering of Common Stock   Benzinga
Sep 22, 2020
10:48PM EDT  Adicet Bio, Inc. Determines Not to Proceed with Public Offering of   GlobeNewswire Inc
10:11AM EDT  Mid-Morning Market Update: Markets Mostly Higher; AutoZone Beats Q4 Estimates   Benzinga
Sep 21, 2020
02:32PM EDT  Mid-Afternoon Market Update: Dow Tumbles 800 Points; Nikola Shares Plummet   Benzinga
12:09PM EDT  Mid-Day Market Update: Crude Oil Drops Over 5%; Roku Shares Spike Higher   Benzinga
10:21AM EDT  Mid-Morning Market Update: Markets Open Lower; Microsoft To Acquire Game Maker ZeniMax For $7.5B   Benzinga
07:07AM EDT  Adicet Bio Commences Underwritten Public Offering Of 4.5 Mln Common Shares   RTTNews
07:07AM EDT  Adicet Bio, Inc. Announces Proposed 4.5M Share Public Offering Of Common Stock   Benzinga
07:00AM EDT  Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Sep 18, 2020
04:10PM EDT  Adicet Bio Announces Inducement Grant Under Nasdaq Listing Rule   GlobeNewswire Inc
Sep 16, 2020
07:22AM EDT  Biotechnology company Adicet Bio, Inc. (ACET) announced the Wednesday the appointment of Nick Harvey as Chief Financial Officer. Harvey will be responsible for leading the company's financial strategy and management of activities related to accounting, capital markets and business operations.   RTTNews
07:12AM EDT  Adicet Bio Appoints Nick Harvey As CFO   RTTNews
07:00AM EDT  Adicet Bio Appoints Nick Harvey as Chief Financial Officer   GlobeNewswire Inc
Sep 15, 2020
04:10PM EDT  Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, will present at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 8:40 AM ET.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC